2-(3-chloro-4-methylphenyl)isoindole-1,3-dione, also known as **N-(3-chloro-4-methylphenyl)phthalimide**, is a synthetic organic compound. It is a derivative of phthalimide, a well-known building block in organic synthesis.
Here's why it's important for research:
* **Versatile building block:** Like phthalimide, it can be used as a precursor for a variety of other organic compounds. The presence of the chloro and methyl substituents on the phenyl ring provides additional functionality and opportunities for modification.
* **Potential applications in pharmaceuticals and materials science:** Its structure can be tailored to create compounds with specific pharmacological activities. It could potentially be used to develop drugs for treating conditions like cancer, inflammation, or infections. Additionally, its properties could be beneficial for developing new materials, such as polymers or coatings.
* **Model system for studying organic reactions:** Due to its relatively simple structure and reactivity, it can be used as a model system to study various organic reactions, such as nucleophilic substitution, Friedel-Crafts alkylation, and cycloadditions. This helps researchers gain a better understanding of chemical reactivity and develop new synthetic methods.
* **Promising precursor for fluorescent probes:** The presence of the phthalimide ring, which is known for its fluorescent properties, makes it a promising precursor for developing fluorescent probes for biological imaging and sensing applications.
**However, it's crucial to note that research on 2-(3-chloro-4-methylphenyl)isoindole-1,3-dione is still ongoing.** Its specific applications and potential benefits are yet to be fully explored. Further research is needed to assess its safety, effectiveness, and practicality for specific applications.
**Overall, 2-(3-chloro-4-methylphenyl)isoindole-1,3-dione is a valuable tool for researchers working in various fields of chemistry, including organic synthesis, medicinal chemistry, and materials science.** Its versatility and potential applications make it a promising compound for future research and development.
ID Source | ID |
---|---|
PubMed CID | 644566 |
CHEMBL ID | 1525557 |
CHEBI ID | 116956 |
SCHEMBL ID | 12173010 |
Synonym |
---|
2-(3-chloro-4-methyl-phenyl)-isoindole-1,3-dione |
smr000009717 |
OPREA1_830139 |
OPREA1_048478 |
MLS000028220 , |
STK247594 |
2-(3-chloro-4-methylphenyl)-1h-isoindole-1,3(2h)-dione |
CHEBI:116956 |
AKOS000715210 |
2-(3-chloro-4-methylphenyl)isoindole-1,3-dione |
SCHEMBL12173010 |
HMS2288I12 |
CHEMBL1525557 |
Q27203565 |
SR-01000321334-1 |
sr-01000321334 |
Class | Description |
---|---|
phthalimides | A dicarboximide that is phthalimide or derivatives obtained from it by the formal replacement of one or more hydrogens. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 11.9955 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 14.5810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
P53 | Homo sapiens (human) | Potency | 15.8489 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 11.2202 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 1.2589 | 0.0200 | 10.7869 | 31.6228 | AID912 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |